» Articles » PMID: 21931001

Antireflux Surgery Preserves Lung Function in Patients with Gastroesophageal Reflux Disease and End-stage Lung Disease Before and After Lung Transplantation

Overview
Journal Arch Surg
Specialty General Surgery
Date 2011 Sep 21
PMID 21931001
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gastroesophageal reflux disease (GERD) is common in patients with end-stage lung disease (ESLD). GERD may cause obliterative bronchiolitis after lung transplantation (LTx), represented by a decline in forced expiratory volume in 1 second (FEV(1)).

Objectives: To identify the patterns of reflux in patients with ESLD and to determine whether antireflux surgery (ARS) positively impacts lung function.

Design: Retrospective review of prospectively collected data.

Setting: Tertiary care university hospital.

Patients: Forty-three patients with ESLD and documented GERD (pre-LTx, 19; post-LTx, 24).

Interventions: Antireflux surgery.

Main Outcome Measures: Reflux patterns including laryngopharyngeal reflux as measured by esophageal impedance, and FEV(1), and episodes of pneumonia and acute rejection before and after ARS.

Results: Before ARS, 19 of 43 patients (44%) were minimally symptomatic or asymptomatic. Laryngopharyngeal reflux events, which occurred primarily in the upright position, were common in post-LTx (56%) and pre-LTx (31%) patients. At 1 year after ARS, FEV(1) significantly improved in 91% of the post-LTx patients (P < .01) and 85% of the pre-LTx patients (P = .02). Of patients with pre-ARS declining FEV(1), 92% of post-LTx and 88% of pre-LTx patients had a reversal of this trend. Episodes of pneumonia and acute rejection were significantly reduced in post-LTx patients (P = .03) or stablilized in pre-LTx patients (P = .09).

Conclusions: There should be a low threshold for performing objective esophageal testing including esophageal impedance because GERD may be occult and ARS may improve or prolong allograft and native lung function.

Citing Articles

Interventional anti-reflux management for gastro-oesophageal reflux disease in lung transplant recipients: a systematic review and meta-analysis.

Krahelski O, Ali I, Namgoong C, Dave K, Reed A, Ashrafian H Surg Endosc. 2024; 39(1):19-38.

PMID: 39586876 PMC: 11666770. DOI: 10.1007/s00464-024-11392-8.


Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure.

Lo W, Muftah M, Goldberg H, Sharma N, Chan W Dis Esophagus. 2024; 37(7).

PMID: 38521967 PMC: 11466852. DOI: 10.1093/dote/doae020.


Enhanced recovery after surgery may mitigate the risks associated with robotic-assisted fundoplication in lung transplant patients.

Wu R, Robayo V, Nguyen D, Chan E, Chihara R, Huang H Surg Endosc. 2024; 38(4):2134-2141.

PMID: 38443500 DOI: 10.1007/s00464-024-10719-9.


Esophageal Motility Abnormalities in Lung Transplant Recipients With Esophageal Acid Reflux Are Different From Matched Controls.

Elsheikh M, Akanbi L, Selby L, Ismail B J Neurogastroenterol Motil. 2023; 30(2):156-165.

PMID: 38062800 PMC: 10999846. DOI: 10.5056/jnm23017.


Abnormal bolus reflux on impedance-pH testing independently predicts 3-year pulmonary outcome and mortality in pulmonary fibrosis.

Bailey M, Borges L, Goldberg H, Hathorn K, Gavini S, Lo W J Gastroenterol Hepatol. 2023; 38(11):1998-2005.

PMID: 37605548 PMC: 10761196. DOI: 10.1111/jgh.16325.